Fig. 1: CONSORT diagram of ChemoID study.

A total of 136 patients were screened between January 31, 2020, and April 15, 2023; Eighty-one of these patients were randomized to either the ChemoID or physician-choice group. The first prespecified interim analysis was performed when 75 subjects were enrolled in the trial.